PDF(Pubmed)
Abstract：
Immune checkpoint inhibitor (ICI) therapy, which targets programmed cell death protein 1, has demonstrated enhanced survival outcomes in numerous patients with cancer. Historically, individuals with autoimmune diseases have been excluded from clinical trials involving cancer immunotherapies due to concerns about the potential worsening of their underlying autoimmune conditions. In the present case report, a patient with non-small cell lung cancer and bullous pemphigoid (BP) who underwent treatment with the ICI pembrolizumab is described. In this specific clinical case, no severe exacerbation of the underlying autoimmune disease was observed. Contrarily, the patient not only tolerated pembrolizumab well but also experienced amelioration of the BP lesions after the treatment. This case challenges the conventional exclusion criteria for ICI therapy in patients with autoimmune diseases, suggesting the potential safety and efficacy of such treatments in this specific population. However, further investigations and larger-scale studies are warranted to validate these findings and provide a more comprehensive understanding of the implications of ICI therapy in patients with autoimmune comorbidities.
摘要：
免疫检查点抑制剂（ICI）治疗，靶向程序性细胞死亡蛋白1,已证明在许多癌症患者中提高了生存结局.历史上,由于担心自身免疫疾病潜在恶化,自身免疫疾病患者已被排除在涉及癌症免疫疗法的临床试验之外.在本案例报告中，本研究描述了1例非小细胞肺癌合并大疱性类天疱疮(BP)患者接受ICI派姆单抗治疗.在这个特定的临床病例中，未观察到基础自身免疫性疾病的严重恶化.相反，患者不仅对pembrolizumab耐受良好,而且治疗后BP病变也得到改善.该病例对自身免疫性疾病患者ICI治疗的常规排除标准提出了挑战，提示此类治疗在该特定人群中的潜在安全性和有效性。然而,需要进一步的调查和更大规模的研究来验证这些发现,并更全面地了解ICI治疗对自身免疫性合并症患者的影响.
